Home
PHAT
PHAT News

Latest Phathom Pharmaceuticals Inc. (PHAT) News on October 29, 2025

MT Newswires

23 days ago

Phathom Pharmaceuticals Names Sanjeev Narula Finance, Business Chief

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

GlobeNewswire

23 days ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Phathom Pharmaceuticals (NASDAQ:PHAT) adds US$64m to market cap in the past 7 days, though investors from five years ago are still down 67%

Simply Wall St.

a month ago

Phathom Pharmaceuticals (NASDAQ:PHAT) adds US$64m to market cap in the past 7 days, though investors from five years ago are still down 67%

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

Zacks

2 months ago

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

GlobeNewswire

4 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

MT Newswires

4 months ago

Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

GlobeNewswire

4 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

MT Newswires

5 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

5 months ago

Top Midday Gainers

MT Newswires

5 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires

5 months ago

Sector Update: Health Care

MT Newswires

5 months ago

Phathom Pharmaceuticals Shares Surge After FDA Grants 10-Year Exclusivity for Acid-Reducing Drug

Investing.com

5 months ago

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

GlobeNewswire

5 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)

Zacks

6 months ago

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target

Simply Wall St.

6 months ago

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target

Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

6 months ago

Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

GuruFocus.com

6 months ago

Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Zacks

6 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

GlobeNewswire

6 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

GlobeNewswire

6 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago

Simply Wall St.

6 months ago

Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

GlobeNewswire

6 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Zacks

7 months ago

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

7 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Phathom Pharmaceuticals Names Steven Basta CEO

Phathom Pharmaceuticals Announces Leadership Succession

GlobeNewswire

7 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

GlobeNewswire

7 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

MT Newswires

7 months ago

Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating

Phathom Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Phathom Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...

GuruFocus.com

8 months ago

Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Zacks

8 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result

GuruFocus.com

8 months ago

Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

GlobeNewswire

8 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

MT Newswires

8 months ago

Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire

9 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?

Simply Wall St.

9 months ago

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?

Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

Insider Monkey

a year ago

Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

MT Newswires

a year ago

Phathom Pharmaceuticals Files US FDA Petition to Seek Voquezna Exclusivity Period

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

GlobeNewswire

a year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Zacks

a year ago

Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Zacks

a year ago

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

a year ago

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

MT Newswires

a year ago

Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a year ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For

GuruFocus.com

a year ago

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%

Simply Wall St.

a year ago

Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

MT Newswires

a year ago

Phathom Pharmaceuticals Prices Underwritten Offering of Shares and Warrants

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

a year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

GlobeNewswire

a year ago

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

MT Newswires

a year ago

Phathom Pharmaceuticals Gets New FDA Approval for Voquezna Tablets

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 07/18/2024

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

GlobeNewswire

a year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

GlobeNewswire

a year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates

Zacks

a year ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

MT Newswires

a year ago

Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

GlobeNewswire

2 years ago

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors

Barrons.com

2 years ago

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors

12 Most Shorted Stocks in 2024

Insider Monkey

2 years ago

12 Most Shorted Stocks in 2024

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

2 years ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

GlobeNewswire

2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Phathom Pharmaceuticals Inc Earnings Call

Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...

GuruFocus.com

2 years ago

Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

2 years ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

GlobeNewswire

2 years ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

GlobeNewswire

2 years ago

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Hawaiian Holdings, Inc. (NASDAQ:HA) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Hawaiian Holdings, Inc. (NASDAQ:HA) Q4 2023 Earnings Call Transcript

10 Highest Quality Egg Brands in the US

Insider Monkey

2 years ago

10 Highest Quality Egg Brands in the US

Denny's shutters only location in Oakland after more than 54 years due to high crime

Fox Business

2 years ago

Denny's shutters only location in Oakland after more than 54 years due to high crime

Hawaiian Holdings (HA) Reports Wider-Than-Expected Loss in Q4

Zacks

2 years ago

Hawaiian Holdings (HA) Reports Wider-Than-Expected Loss in Q4

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

2 years ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

PR Newswire

2 years ago

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

Coastal Financial Corporation Announces Fourth Quarter and Fiscal Year 2023 Results

GlobeNewswire

2 years ago

Coastal Financial Corporation Announces Fourth Quarter and Fiscal Year 2023 Results

Garrett Motion (NASDAQ:GTX) investors are sitting on a loss of 46% if they invested five years ago

Simply Wall St.

2 years ago

Garrett Motion (NASDAQ:GTX) investors are sitting on a loss of 46% if they invested five years ago

With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors

Simply Wall St.

2 years ago

With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors

I Want To Add An Investment Property To My Retirement Portfolio. Should I Focus On Cash Flow Or Appreciation?

Benzinga

2 years ago

I Want To Add An Investment Property To My Retirement Portfolio. Should I Focus On Cash Flow Or Appreciation?

Where Will Novavax Be in 5 Years?

Motley Fool

2 years ago

Where Will Novavax Be in 5 Years?

Better Stock to Buy: Etsy vs. Beyond Meat

Motley Fool

2 years ago

Better Stock to Buy: Etsy vs. Beyond Meat

Southside Bancshares (SBSI) Lags Q4 Earnings and Revenue Estimates

Zacks

2 years ago

Southside Bancshares (SBSI) Lags Q4 Earnings and Revenue Estimates

LegalZoom to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

GlobeNewswire

2 years ago

LegalZoom to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

Share on Social Networks: